ICMR removes Ivermectin, HCQ from revised guidelines

AIIMS had earlier said the antiparasitic medicine Ivermectin did not reduce the viral load

226
ICMR

Last Updated on September 28, 2021 by The Health Master

The Indian Council of Medical Research and the C-19 National Task Force have dropped the usage of Ivermectin and Hydroxychloroquine (HCQ) drugs from their revised “clinical guidance for management of adult C-19 patients”.

However, both the medicines can be used with caution in a climax trial setting. According to reports, experts of the government bodies did not find enough evidence of a potential therapeutic effect of the widely used medicines against coronavirus.

A study by the All India Institute of Medical Sciences (AIIMS) had earlier said the antiparasitic medicine Ivermectin did not reduce the viral load or duration of symptoms in patients with C-19 even at higher doses.

This was found in a randomised controlled trial on 157 patients admitted with mild to moderate disease at the premier hospital during the first surge of infections between July and September last year.

A report in The Hindu Business Line said Hydroxychloroquine was dropped because of no mortality benefit, increased risk of address drug effect (ADE) when co-administered with Azithromycin.

Studies also found there was no clarity on mortality benefit, no effect on length of stay and clinical recovery in case of Ivermectin.

The World Health Organisation had warned against use of Ivermectin a day after Goa health minister Vishwajit Rane recommended the medicine for all adult residents of the coastal state to fight the deadly virus.

Ivermectin

Hydroxychloroquine

FAQs on use of hydroxychloroquine (HCQ)

PM to launch Pradhan Mantri Digital Health Mission on 27th

Govt approves Medical Device Park off Yamuna Expressway

24 weeks cap for MTP in special cases comes into force

We need to be vigilant towards counterfeit products: ASPA

Govt recommends imposition of Anti Dumping duty on APIs

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner